New Small-Scale Expression Packages: RushMab™- Ready in just 8 days! LEARN MORE

Biointron Insights: Antibody Industry Report (Q1 2024 Insights, Trends & Analysis) LEARN MORE

Antibody Antibody Antibody

Services & Products

Why you should choose us

  • Pioneering Antibody Solutions

    We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.

  • Unique Cell Line Commercialization

    We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.

  • Global Collaborative Excellence

    Our partnerships with over 1,500 global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.

  • Trust and Exclusive ownership

    We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Antibody

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.


Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies all over the world.

Read More Read More

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

The 4th Fc-Mediated Function Summit 2024 was held in Boston, MA from April 17-18, and focused on discussions supercharging FcRn, FcγR, and IgG to advance molecular development, clinical utility, and novel therapeutic applications.

Apr 22, 2024
Blog

Welcome back to Antibody Basics by Biointron, Part 6. In this episode, we’ll talk about Antibody-Drug Conjugates (ADCs), the drug type taking the biopharmaceutical industry by storm.What are antibody-drug conjugates (ADCs)?Composed of a monoclonal antibody (mAb) covalently bonded to a biologically

Apr 19, 2024
Blog

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Mar 23, 2024
Company News

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Mar 15, 2024
Company News

Celebrate International Women's Day with Biointron's female workforce!

Mar 15, 2024
Company News

Join Biointron at a fun sticker collection game during AACR 2024! Keep an eye on our social media! During this game period, Biointron will continue our daily social postings with Dr.Youngs hidden here and there! Take a screenshot every time you spot one, collect 25+ and win AirPods!

Mar 28, 2024
Dr.Young

The Biointron team is excited to announce our participation in the Festival of Biologics 2024.

Dec 14, 2023
Upcoming Events

Biointron is thrilled to be part of the 4th Fc-Mediated Function Summit, a pivotal event focusing on the latest developments in FcRn, FcγR, and IgG, aiming to enhance related therapeutic applications. This unique conference, happening in Boston from April 16-18, 2024, will be gathering over 80 specialists in the field to share insights on molecular engineering and clinical outcomes.

Mar 20, 2024
Upcoming Events

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.